NK3 receptor antagonists, or NKB antagonists, are a class of drugs that target the neurokinin 3 (NK3) receptors in the brain.
Neurokinins are a group of peptides that act as neurotransmitters in the central and peripheral nervous systems.
NK3 receptors are a type of receptor that binds to these peptides.
NKB antagonists have potential therapeutic uses in various conditions related to the brain and reproductive system: menopausal symptoms, including hot flashes and mood disturbances, as well as potential applications in disorders such as schizophrenia, depression, and anxiety.
By blocking the action of NKB at the NK3 receptors, these antagonists aim to modulate the balance of neurotransmitters within the brain, potentially leading to therapeutic benefits.
NKB antagonist are useful for patient, unable or refusing to take menopausal hormone therapy.
NKB antagonist are not appropriate for treating either premature ovarian insufficiency or bothersome vasomotor symptoms and osteoporosis as both require hormonal therapy.